Creator of Relanza says : "Tamiflu is an imitation" ! and "Per hour when Tamiflu meets more and more case of resistance and counter-indication - what strongly worries me - I can only recommend the recourse to Relenza."
Le Pr Mark von Itzstein, 51 ans, Australien d’origine allemande, dirige un institut de recherche au sein de l’université de Griffith. Il a créé, en 1989, dans une autre université, le Relenza, beaucoup moins connu que le Tamiflu mais qui rencontre moins de résistance.
Paris Match. Les avis semblent unanimes : si le Tamiflu connaît un succès commercial bien plus important que le Relenza, c’est parce qu’il s’absorbe alors que l’on doit inhaler le Relenza. Qu’en pensez-vous ? Pr Mark von Itzstein. Le Relenza a été créé en premier, et le Tamiflu en est une imitation – qui a bénéficié d’une stratégie marketing plus importante, plus offensive, donc a généré beaucoup plus de profits pour le laboratoire le fabriquant et le commercialisant. Mais il est vrai que sa présentation le rend plus facile d’utilisation que le Relenza, difficile à inhaler en cas d’inflammation des voies respiratoires. A l’heure où le Tamiflu rencontre de plus en plus de cas de résistance et de contre-indication – ce qui me préoccupe fortement – je ne peux que recommander le recours au Relenza. ---------------------------------------------------------- babelfih-translation:
Pr Mark von Itzstein, creator of Relenza. Pr Mark von Itzstein, 51 years, Australian of German origin, directs an research institute within the university of Griffith. It created, in 1989, in another university, Relenza, much less known than Tamiflu but which meets less resistance. Paris Match. The opinions seem unanimous: if Tamiflu is a business success much more important than Relenza, it is because it is absorbed whereas one must inhale Relenza. What do you think about it? Pr Mark von Itzstein. Relenza was created in first, and Tamiflu is an imitation - which profited from a more important strategy marketing, more offensive, therefore generated much more profits for the laboratory manufacturing it and marketing it. But it is true that its presentation makes it easier to use than Relenza, difficult to inhale in the event of ignition of the respiratory tracts. Per hour when Tamiflu meets more and more case of resistance and counter-indication - what strongly worries me - I can only recommend the recourse to Relenza.
